Palvella Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2023	FY 2022	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Jun '22 Jun 30, 2022
Selling, General & Admin	6.38	5.94	3.08	16.85	16.39	16.39
Research & Development	22.35	8.15	8.79	41.8	52.98	52.98
Total Operating Expenses	28.73	14.1	11.87	58.65	69.38	69.38
Operating Income	-28.73	-14.1	-11.87	-58.65	-69.38	-69.38
Interest Income	-	-3.89	6.27	-	0.72	0.72
Interest Expense	-4.26	-0.43	-	-	-	-
Other Non-Operating Income (Expense)	-5	-1.22	24.3	-	6.87	8.17
Total Non-Operating Income (Expense)	-9.26	-5.54	30.56	-	7.59	8.89
Pretax Income	-37.98	-19.63	18.69	-58.65	-61.79	-60.48
Net Income	-32.37	-17.43	17.92	-24.54	-33.28	-33.28
Net Income Attributable to Preferred Dividends	-0.58	-	0.78	-	-	-
Net Income to Common	-32.37	-17.43	17.92	-24.54	-33.28	-33.28
Shares Outstanding (Basic)	3,695	2	2	3	6	6
Shares Outstanding (Diluted)	3,695	2	2	3	6	6
Shares Change (YoY)	525.04%	24.08%	-30.55%	-54.83%	-	608.81%
EPS (Basic)	-2.51	-7.83	2.19	2.19	-4.82	-4.82
EPS (Diluted)	-2.51	-7.83	2.17	2.17	-4.82	-4.82
Free Cash Flow	-22.59	-10.84	-13.7	-53.82	-60.97	-60.97
Free Cash Flow Per Share	-0.01	-4.87	-7.64	-20.84	-10.66	-10.66
EBITDA	-28.73	-14.1	-11.87	-58.65	-66.6	-66.6
EBIT	-28.73	-14.1	-11.87	-58.65	-69.38	-69.38

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q